Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 (hospitalized or not) meta-analysis

Abu Esba LC (any NSAID use, acute and chronic) OBSnon-steroidal anti-inflammatory drugscontrolCOVID-19 (hospitalized or not)NA
146/357 safety concern
  • inconclusive 51 % decrease in deaths (PE)
  • statistically significant 54 % increase in hospitalization
Gianfransesco OBSnon-steroidal anti-inflammatory drugscontrolCOVID-19 (hospitalized or not)NA
111/420 inconclusive
    Park OBSnon-steroidal anti-inflammatory drugsparacetamolCOVID-19 (hospitalized or not)NA
    		397/397 inconclusive
      Manenti OBScolchicinestandard of careCOVID-19 (hospitalized or not)NA
      		-/- suggested
      • suggested 76 % decrease in deaths,deaths (time to event analysis only)
      Lund OBSnon-steroidal anti-inflammatory drugscontrolCOVID-19 (hospitalized or not)NA
      		248/8988 inconclusive
      • inconclusive 2 % increase in deaths (PE)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons